Pertuzumab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CONITEC (Brazil), DMC (Denmark) and G-BA (Germany), among others, recommended or restricted pertuzumab, while CIPM (Spain) did not recommend it.
On the same population the two systems disagree outright: SMC (Scotland) recorded restricted for “In combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with human epidermal growth factor receptor 2 (HER2)-positive early breast c…”, while PBAC (Australia) recorded not recommended for “Human epidermal growth factor receptor-2 positive (HER2+) early breast cancer (EBC)”.
The file has been open for more than a decade: 12.9 years separate the first record, 16 May 2013 at AWMSG (Wales), from the most recent, 29 Apr 2026 at DMC (Denmark).
NYE METODER (Norway) changed its position: not recommended on 13 Nov 2016, recommended by 16 Jun 2019, after a resubmission.
No assessment is on file from TLV (Sweden), which is among the eight highest-volume agencies here.
The file is active: 4 of 32 records date from 2023 or later.
The programme is broad: 12 distinct indication wordings are recorded for pertuzumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
5 of these 32 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess pertuzumab, on 16 May 2013; DMC (Denmark) did not open a file until 29 Apr 2026 — an unusually long tail of 12.9 years between the earliest and latest system to look at it.
The record arrives in waves: 7 separate years each carry two or more decisions, spread across 13 years in total.
9 of the 13 agencies here assessed pertuzumab more than once, PBAC (Australia) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
pertuzumab has been through 13 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for pertuzumab reads 12 recommended, 10 not recommended, 3 restricted and 2 other, with 5 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2025 | Human epidermal growth factor receptor 2-positive (HER2+) locally advanced, inflammatory or early stage breast cancer | Recommended | source |
| PHARMAC (New Zealand) | 21 Jul 2023 | Breast cancer, HER2-positive, locally advanced, inflammatory or early-stage, neoadjuvant treatment | PTAC advice: No Formal Recommendation | source |
| CIPM (Spain) | 5 May 2022 | Indicaciones terapéuticas autorizadas: Cáncer de mama precoz Perjeta está indicado en combinación con trastuzumab y quim… | not financed by the SNS · art. 92 c, d | source |
| ZIN (Netherlands) | 11 May 2021 | Pakketadvies sluisgeneesmiddel pertuzumab en trastuzumab (Phesgo®) bij borstkanker | advice published (sluis) | source |
| G-BA (Germany) | 18 Feb 2016 | Perjeta — benefit assessment §35a | added benefit: not proven | source |
27 further decisions for pertuzumab, across 12 agencies, are not shown here. They include the most recent record on file, 29 Apr 2026 from DMC (Denmark); its outcome is in the subscriber dataset. They link to 21 further source documents.
Related molecules
- neratinib — divergent outcome (recommended vs not recommended) on a shared indication
- pembrolizumab — same ATC class L01F — Antineoplastics
- nivolumab — same ATC class L01F — Antineoplastics
- daratumumab — same ATC class L01F — Antineoplastics
- rituximab — same ATC class L01F — Antineoplastics
- bevacizumab — same ATC class L01F — Antineoplastics
Coverage: 32 decisions for pertuzumab from 13 agencies, 2013 to 2026. Data to 7 Sep 2026. ATC class L01F — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.